Topic: central nervous system
Impel’s championing of nasal delivery of drugs has been rewarded with new financing that will help it advance three drugs through the clinic.
Neurimmune's antibody targets the misfolded SOD1 protein that has been implicated in a subset of ALS cases.
Domain Therapeutics has another big pharma partner, signing a deal with Boehringer Ingelheim to develop new drugs for CNS disorders.
Discovery made by Virginia Tech scientists on perineuronal nets could open up new approach for acquired epilepsy.
New data on Biogen and Eisai’s BAN2401 at CTAD was supposed to answer concerns about its main study—but investors don’t seem too impressed.
Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel.
A Tufts University-led team has developed 3D models of the central nervous system that might prove useful for drug discovery.
The collaboration gives Neurocrine a potential source of small molecules to treat disorders of the central nervous system.
Supernus makes a return to epilepsy R&D, buying the developer of a traditional Chinese medicine-derived drug for $15 million upfront.
VistaGen Therapeutics has licensed Pherin Pharmaceuticals' lead candidate, a nasal spray for social anxiety disorder.